In the prospective randomized controlled PONTIAC trial (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease) measurement of NT-proBNP (cut-off 125 pg/ml) was used to identify T2DM patients at high risk for developing CVD [19]. This evidence concerns the gene NPPB and type 2 diabetes mellitus.